Aspen Aerogels, Inc. (NYSE:ASPN) Given Average Recommendation of “Moderate Buy” by Brokerages

Aspen Aerogels, Inc. (NYSE:ASPN) has received an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $19.50.

Several analysts have recently weighed in on the stock. Oppenheimer downgraded shares of Aspen Aerogels from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 8th. Canaccord Genuity Group decreased their price target on shares of Aspen Aerogels from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Barclays downgraded shares of Aspen Aerogels from an “equal weight” rating to an “underweight” rating and lifted their price target for the company from $7.00 to $16.00 in a research note on Monday, August 11th.

Aspen Aerogels Stock Down 1.9%

Shares of NYSE ASPN opened at $6.83 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.98 and a quick ratio of 3.31. The company has a market cap of $562.52 million, a P/E ratio of -1.79 and a beta of 2.65. Aspen Aerogels has a 1 year low of $4.16 and a 1 year high of $30.24. The firm has a 50-day simple moving average of $7.03 and a two-hundred day simple moving average of $6.56.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings data on Thursday, August 7th. The construction company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.08. Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The business had revenue of $78.02 million during the quarter, compared to the consensus estimate of $72.53 million. During the same quarter last year, the firm earned $0.21 earnings per share. The firm’s quarterly revenue was down 33.8% compared to the same quarter last year. Aspen Aerogels has set its FY 2025 guidance at -3.860–3.730 EPS. Research analysts anticipate that Aspen Aerogels will post 0.17 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Santhosh P. Daniel sold 4,410 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.31, for a total value of $32,237.10. Following the completion of the transaction, the chief accounting officer owned 19,879 shares of the company’s stock, valued at $145,315.49. The trade was a 18.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aspen Aerogels

A number of large investors have recently made changes to their positions in the business. Caxton Associates LLP increased its position in shares of Aspen Aerogels by 114.9% in the 2nd quarter. Caxton Associates LLP now owns 103,172 shares of the construction company’s stock valued at $611,000 after acquiring an additional 55,167 shares during the period. FORA Capital LLC grew its position in Aspen Aerogels by 138.2% during the 2nd quarter. FORA Capital LLC now owns 29,452 shares of the construction company’s stock worth $174,000 after purchasing an additional 17,090 shares during the period. Tower Research Capital LLC TRC grew its position in Aspen Aerogels by 184.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,235 shares of the construction company’s stock worth $43,000 after purchasing an additional 4,693 shares during the period. Voleon Capital Management LP grew its position in Aspen Aerogels by 464.8% during the 2nd quarter. Voleon Capital Management LP now owns 248,839 shares of the construction company’s stock worth $1,473,000 after purchasing an additional 204,779 shares during the period. Finally, HRT Financial LP grew its position in Aspen Aerogels by 668.7% during the 2nd quarter. HRT Financial LP now owns 595,742 shares of the construction company’s stock worth $3,526,000 after purchasing an additional 518,243 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.